Literature DB >> 15823453

Rapid onset of tolerance to beta-agonist bronchodilation.

Sarah Haney1, Robert J Hancox.   

Abstract

INTRODUCTION: Regular use of beta-agonists leads to tolerance to their bronchodilator effects. This is easily demonstrated if dilation is tested following methacholine challenge. It is not known how quickly tolerance develops or how long it lasts after stopping beta-agonist therapy.
METHODS: Ten subjects with stable asthma were studied. Following 2 weeks without beta-agonists, methacholine was inhaled to induce a 20% reduction in FEV1. The response to inhaled salbutamol (100, 100, 200 microg at 5-min intervals) was then measured. This procedure was repeated 24 h after one dose and 24 h after 3, 7 and 14 days of inhaled formoterol 12 microg twice daily, and 3 and 5 days after formoterol was discontinued. Unscheduled use of beta-agonists was not permitted.
RESULTS: Bronchodilator tolerance, assessed by a reduction of the area under the salbutamol dose-response curve, occurred after 1 dose of formoterol (28% reduction, 95% CI 12, 45%), increased up to 1 week and plateaued between 1 and 2 weeks (58% reduction, 95% CI 38, 78%). Three days after stopping formoterol, the response to salbutamol was similar to baseline (12% reduction, 95% CI -9, 33%). The first dose of formoterol provided significant bronchoprotection to methacholine (1.6 doubling doses, P=0.007). This diminished with regular treatment and by 2 weeks the PD20 methacholine was not significantly different to baseline.
CONCLUSIONS: Bronchodilator tolerance occurs after a single dose and reaches a maximum after 1 week of regular formoterol. Sensitivity recovers 3 days after stopping treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15823453     DOI: 10.1016/j.rmed.2004.10.014

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

Review 1.  Asthma, outdoor air quality and the Olympic Games.

Authors:  Donald C McKenzie; Louis-Philippe Boulet
Journal:  CMAJ       Date:  2008-08-07       Impact factor: 8.262

Review 2.  Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.

Authors:  Steven J Charlton
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

3.  Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.

Authors:  Juan Carlos Cardet; Xiaofeng Jiang; Quan Lu; Norma Gerard; Kristen McIntire; Homer A Boushey; Mario Castro; Vernon M Chinchilli; Christopher D Codispoti; Anne-Marie Dyer; Fernando Holguin; Monica Kraft; Stephen Lazarus; Robert F Lemanske; Njira Lugogo; Dave Mauger; Wendy C Moore; James Moy; Victor E Ortega; Stephen P Peters; Lewis J Smith; Julian Solway; Christine A Sorkness; Kaharu Sumino; Michael E Wechsler; Sally Wenzel; Elliot Israel
Journal:  J Allergy Clin Immunol       Date:  2019-03-11       Impact factor: 10.793

Review 4.  Recovery from bronchoconstriction and bronchodilator tolerance.

Authors:  Sarah Haney; Robert J Hancox
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 5.  beta2-Agonists at the Olympic Games.

Authors:  Kenneth D Fitch
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 6.  Beta2-agonists and exercise-induced asthma.

Authors:  Sandra D Anderson; Corinne Caillaud; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

7.  Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic subjects.

Authors:  Jimmi Elers; Ulla Strandbygaard; Lars Pedersen; Vibeke Backer
Journal:  Open Respir Med J       Date:  2010-04-21

8.  Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD.

Authors:  Donald P Tashkin; Ning Li; David Halpin; Eric Kleerup; Marc Decramer; Bartolome Celli; Robert Elashoff
Journal:  Respir Med       Date:  2013-08-22       Impact factor: 3.415

9.  Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.

Authors:  John D Brannan; M Diane Lougheed
Journal:  Front Physiol       Date:  2012-12-10       Impact factor: 4.566

10.  Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial.

Authors:  J Lötvall; P S Bakke; L Bjermer; S Steinshamn; C Scott-Wilson; C Crim; L Sanford; B Haumann
Journal:  BMJ Open       Date:  2012-01-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.